The Trump administration is negotiating with pharmaceutical companies to increase drug prices in Europe and other regions to reduce costs in the United States. Past studies indicate drugmakers generate sufficient revenue in the U.S. to cover their global research and development expenses. The administration prioritizes these discussions despite potential political challenges in Europe, where existing spend controls could complicate price adjustments. Over 30 industry leaders have urged the European Union to reconsider its pricing policies, reflecting the strategy's significance to the U.S. market.
"Prices can come down in the United States without being increased in other countries, and we can still get innovation," she said.
Despite the Trump administration's tariff threats and pressure to move more manufacturing to the U.S., the push to raise European drug prices is its top priority in discussions with industry.
Kaltenboeck said past studies had shown that drugmakers made enough money in the U.S. to more than fund their entire global R&D spends.
"It's going to be very difficult for a country that already has the ability to control what it spends to go in the other direction," Kaltenboeck said, "and it doesn't make much sense for them politically."
Collection
[
|
...
]